Novartis.com | Contact Us | Help | Site Map | Stay Connected | Large Text VersionRegular Text Version

Welcome to Novartis Oncology - The Global Site

 

 

 

Novartis Oncology Information For Healthcare Professionals

Health Care Professionals

**** Oncology News is a current news service provided by Doctor's Guide®. Novartis accepts no responsibility for and makes no representations or warranties regarding the content of the information presented. ****

Case report of a 2-year-old child with palpebral rhabdomyosarcoma

Rhabdomyosarcoma is an extremely virulent rare tumor whose early diagnosis considerably improves survival and visual prognosis. We report the case of a 2-year-old child with levator palpebrae superioris muscle rhabdomyosarcoma revealed by a sudden and isolated blepharoptosis. Initially, clinical and imaging investigations did not show any abnormality but a painful tumor with some hematoma quickly developed, so the investigations were repeated. The CT-scan showed an extra-conal tumor that had developed at the superior part of the orbit. Histology confirmed the diagnosis of embryonic rhabdomyosarcoma. Because of its results, treatment consisting of chemotherapy associating ifosfamide, vincristine, actinomycin and orbital radiotherapy of 40 Gy with a local addition of 10 Gy were administrated with successful results after a 3-year-follow-up.

ABOUT NOVARTIS ONCOLOGY

Learn More About Novartis Oncology

We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.

RESEARCH INNOVATION

Novartis maintains the most promising oncology drug pipeline in the industry to treat and help people around the world.